TOP STORIES

• BUSINESS GSK Japan Resurrects “Sales” for Rep Performance Review, Doctor Payments; Critics Say It’s a Rollback
  February 20, 2020

• BUSINESS Japan Pharma Market Logs 1st Growth in 3 Years in 2019, Keytruda Is the Best-Seller: IQVIA
  February 19, 2020

• REGULATORY Authorized Generics for Memary, Celecox among Approval List towards June Listing
  February 18, 2020

• REGULATORY MHLW Panel to Review Nippon Shinyaku’s Oligonucleotide DMD Drug, Latuda and More on Feb. 28
  February 18, 2020

• REGULATORY Zolgensma Up for Japan Advisory Panel Meeting on Feb. 26, Listing Expected as Early as May
  February 17, 2020

• BUSINESS Eisai Pulls Belviq from US Market after FDA Flags Cancer Risks
  February 17, 2020

• REGULATORY MHLW to Weigh All-Year Invitation for Sakigake Requests: Top Pharmacy Officer
  February 14, 2020

• BUSINESS Ono Revamps Japan Sales Structure to Gear Up for New Launches
  February 13, 2020

• REGULATORY MHLW Calls for Stable Supplies of HIV Drugs amid Coronavirus Outbreak
  February 13, 2020

• BUSINESS With 2 New Deals Inked, Meiji Hunkering Down for Full-Scale Entry into Hematology Market
  February 12, 2020

• ORGANIZATION FPMAJ Creates Scheme to Deal with Drug Supply Disruptions; Companies to Set Up “Supply Adjustment Teams”
  February 12, 2020

• INTERVIEW Improper Materials Apparently Decreased after Promotion Guidelines Introduced: Pharmacist
  February 10, 2020

• BUSINESS With Orix Deal, Reborn Kobayashi Kako Aims to Become Follow-Up to Big 3 Generic Players
  February 7, 2020

• ORGANIZATION RAD-AR Council Accelerating Initiative to Prepare Medication Guides in English toward Tokyo 2020 Olympic and Paralympic Games
  February 6, 2020

• ORGANIZATION Japan Red Cross Set to Push Formularies at All Group Hospitals, Despite Medical Fee Plan Dropped
  February 5, 2020

• BUSINESS Oncolys Hopes for Chugai’s Participation in US Development of Telomelysin: Chief
  February 4, 2020

• BUSINESS Opdivo Sales Drop 4.7% in April-December, but Ono Secures Higher Profits
  February 3, 2020

• BUSINESS Chugai Ups Core EPS CAGR Target to “Around 30%”: 3-Year Biz Plan
  January 31, 2020

• BUSINESS Chugai’s 2019 Earnings Renews Record for Third Year on Hemlibra, Tecentriq
  January 31, 2020

• REGULATORY Takeda’s RCC Drug Cabometyx Now in Line for March Approval; Alecensa, Rozlytrek Opdivo and More
  January 30, 2020

ページ

• « 先頭
• ‹ Prev
• …
• 118
• 119
• 120
• 121
• 122
• 123
• 124
• 125
• 126
• …
• Next ›
• 最終 »